Lassaletta et al. carried out a global analysis in BRAFV600E-mutated low-grade pediatric gliomas showing that the presence of this BRAF mutation confers a poor outcome with conventional therapies, comparing BRAFV600E-mutant gliomas either with BRAF WT gliomas or with KIAA1549-BRAF-mutant tumors [132]. This evidence concerns the gene BRAF and glioma.